USPTO Examiner DEAK LESLIE R - Art Unit 3799

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19077384SYSTEM AND METHOD FOR COLLECTING PLASMAMarch 2025May 2025Allow310YesNo
18871508PERFORATING DEVICEDecember 2024March 2025Allow400YesNo
18955269SYSTEM AND METHOD FOR COLLECTING PLASMANovember 2024March 2025Allow410NoNo
18936174APPARATUS FOR DRAWING MEDICINE FROM A MEDICINE CONTAINER TO A SYRINGENovember 2024January 2025Allow300NoNo
18792233METHODS AND SYSTEMS FOR TRANSCAVAL TREATMENT OF ANEURYSMSAugust 2024January 2025Allow611YesNo
18747453BLOOD-GAS EXCHANGE DEVICE AND METHODS OF USEJune 2024September 2024Allow300NoNo
18672118SYSTEMS AND METHODS FOR REMOVING UNDESIRABLE MATERIAL WITHIN A CIRCULATORY SYSTEMMay 2024December 2024Allow710NoNo
18641626SYSTEMS AND METHODS FOR REMOVING UNDESIRABLE MATERIAL WITHIN A CIRCULATORY SYSTEMApril 2024September 2024Allow410NoNo
18634734METHODS AND SYSTEMS FOR TRANSCAVAL TREATMENT OF ANEURYSMSApril 2024January 2025Allow911YesNo
18627596MULTI-VIAL ADAPTERS FOR RECONSTITUTING OR DILUTING LYOPHILIZED OR CONCENTRATED DRUG PRODUCTSApril 2024December 2024Allow820YesNo
18623033INTEGRATED URINE ANAEROBIC COLLECTION AND CULTURE APPARATUSApril 2024August 2024Allow400NoNo
18419262METHODS AND SYSTEMS FOR TRANSCAVAL TREATMENT OF ANEURYSMSJanuary 2024July 2024Allow501YesNo
18407218DEVICES FOR BLOOD CAPTURE AND REINTRODUCTION DURING ASPIRATION PROCEDUREJanuary 2024August 2024Allow710NoNo
18380909ONCODIALYSIS SYSTEM AND METHOD FOR PERSONALIZED AUTOLOGOUS CANCER VACCINE AND BLOOD PURIFICATIONOctober 2023August 2024Allow1020YesNo
18473203EYE STENTS AND DELIVERY SYSTEMSSeptember 2023April 2024Allow610YesNo
18342447Dialysis Sheath For Use In Accessing A Dialysis Arteriovenous Graft Or Fistula And Methods Of UseJune 2023January 2024Allow710YesNo
18254741SECURE RECONSTRUCTION DEVICEMay 2023November 2023Allow500NoNo
18129866ONCODIALYSIS SYSTEM AND METHOD FOR PERSONALIZED CANCER VACCINE AND BLOOD PURIFICATIONApril 2023April 2024Allow1321YesNo
18171651URETERAL STENT ASSEMBLY AND STENT PUSHER THEREOFFebruary 2023June 2025Allow2700YesNo
18171639EXTRACORPOREAL BLOOD FILTERING MACHINE AND METHODSFebruary 2023February 2024Abandon1210NoNo
18165664SELF-SEALING TRABECULECTOMYFebruary 2023May 2025Allow2700NoNo
18018826FILTER SYSTEM FOR A CLOSED FLUID-TRANSFER SYSTEM WITH PRESSURE EQUALIZATIONJanuary 2023May 2025Allow2700YesNo
18092235FLUID TRANSFER COUPLINGSDecember 2022December 2023Allow1212NoNo
17914399SURGICAL METHOD, DEVICE, SYSTEM AND KIT FOR THE TREATMENT OF HYDROCEPHALUSSeptember 2022May 2025Allow3201YesNo
17933593PERFUSION DOSAGE FORMSeptember 2022April 2023Allow720NoNo
17943410SYSTEM AND METHOD FOR COLLECTING PLASMASeptember 2022April 2023Allow710NoNo
17802254INTRAOCULAR SHUNTS WITH LOW-PROFILE ACTUATION ELEMENTS AND ASSOCIATED SYSTEMS AND METHODSAugust 2022March 2023Allow600NoNo
17814542CASSETTE APPARATUS UTILIZING ELECTRIC FIELD FOR PROCESSING OF BLOOD TO NEUTRALIZE PATHOGEN CELLS THEREINJuly 2022August 2023Allow1300NoNo
17814549CASSETTE APPARATUS UTILIZING VENTING FOR PROCESSING OF BLOOD TO REMOVE PATHOGEN CELLS THEREINJuly 2022September 2023Allow1400NoNo
17838066Method and Apparatus for Implant in the Conventional Aqueous Humor Outflow Pathway of a Mammalian EyeJune 2022April 2023Allow1010YesNo
17834031DEVICE AND METHOD FOR PERFUSING A SUBJECT'S HEART VIA THE CORONARY SINUSJune 2022February 2023Allow920YesNo
17824789CURVED MICROTUBE FOR TREATING GLAUCOMAMay 2022June 2025Allow3710YesNo
17765590ADJUSTABLE FLOW GLAUCOMA SHUNTS AND ASSOCIATED SYSTEMS AND METHODSMarch 2022October 2022Allow600NoNo
17763163Medical Devices and Methods Thereof for Determining Bacterial Infections in BloodMarch 2022December 2022Allow901NoNo
17701378Implantable Shunt System and MethodMarch 2022June 2025Allow3910NoNo
17684544SHUNTING SYSTEMS WITH ROTATION-BASED FLOW CONTROL ASSEMBLIES, AND ASSOCIATED SYSTEMS AND METHODSMarch 2022April 2025Allow3700YesNo
17675044PURGER DEVICE FOR OXYGENATORSFebruary 2022March 2025Allow3600NoNo
17651636CONTROLLED DRUG DELIVERY OCULAR IMPLANTS AND METHODS OF USING SAMEFebruary 2022June 2025Allow3910YesNo
17669883Methods of Amelioration of Cerebrospinal Fluid and Devices and Systems ThereforFebruary 2022March 2025Allow3711NoNo
17589454System for Washing Red Blood Cells to Reduce HemolysisJanuary 2022December 2024Allow3411YesNo
17569329EYE STENTS AND DELIVERY SYSTEMSJanuary 2022April 2025Allow3910NoNo
17606661ADJUSTABLE FLOW GLAUCOMA SHUNTS AND ASSOCIATED SYSTEMS AND METHODSOctober 2021August 2022Allow1010YesNo
17506565ADJUSTABLE SHUNTS AND ASSOCIATED SYSTEMS AND METHODSOctober 2021March 2025Allow4110NoNo
17500224ADJUSTABLE FLOW GLAUCOMA SHUNTS AND METHODS FOR MAKING AND USING SAMEOctober 2021November 2024Allow3700NoNo
17500210ADJUSTABLE FLOW GLAUCOMA SHUNTS AND METHODS FOR MAKING AND USING SAMEOctober 2021November 2024Allow3700NoNo
17498422BLOOD CIRCULATION SYSTEMOctober 2021February 2025Allow4010NoNo
17444960METHOD FOR CONTROLLING PLACEMENT OF INTRAOCULAR IMPLANTSAugust 2021October 2024Allow3800NoNo
17428561PLATELET LYSATE PRODUCTION METHOD, PRODUCTION SYSTEM, AND BAG SETAugust 2021April 2025Allow4421YesNo
17427155LIQUID TRANSFER DEVICEJuly 2021May 2022Allow1010NoNo
17388796DEVICES FOR ACCESSING MEDICINAL FLUID FROM A CONTAINERJuly 2021March 2025Allow4310NoNo
17369127METHOD FOR EXTRACORPOREAL BLOOD PURIFICATION AND DIALYSATE DISPOSALJuly 2021January 2025Allow4310NoNo
17345544METHODS AND SYSTEMS FOR ESTABLISHING RETROGRADE CAROTID ARTERIAL BLOOD FLOWJune 2021July 2024Allow3700NoNo
17303857IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAMEJune 2021September 2024Allow3910NoNo
17299055Implantable Shunt System and MethodJune 2021February 2022Allow910NoNo
17317455DEVICES AND METHODS FOR NEEDLELESS AND NEEDLED EXTRACTION OF CONTENTS FROM VIALSMay 2021September 2024Allow4110NoNo
17291771Ureteral Catheter StructureMay 2021August 2024Allow4000NoNo
17242464IMPLANTABLE RENAL REPLACEMENT THERAPY DEVICEApril 2021August 2021Allow410NoNo
17239609METHOD AND SYSTEM FOR CONTROLLED HYPERTHERMIAApril 2021November 2021Allow700NoNo
17237733METHOD OF PURGING A BLOOD PUMPApril 2021March 2025Abandon4730NoYes
17237911METHODS AND SYSTEMS FOR ESTABLISHING RETROGRADE CAROTID ARTERIAL BLOOD FLOWApril 2021September 2024Allow4110NoNo
17231697HYBRID VENOUS RESERVOIRApril 2021April 2022Allow1210YesNo
17223534APPARATUS AND METHOD FOR RAPIDLY COOLING OR HEATING THE BODY TEMPERATURE OF A PATIENTApril 2021September 2024Allow4110NoNo
17205400SYSTEM AND METHOD FOR COLLECTING PLASMAMarch 2021September 2024Allow4210NoNo
17205374SYSTEM AND METHOD FOR COLLECTING PLASMAMarch 2021August 2024Allow4110NoNo
17203284ADJUSTABLE SHUNTS AND ASSOCIATED SYSTEMS AND METHODSMarch 2021September 2021Allow610YesNo
17178066IMPLANTABLE BIOLOGIC STENT AND SYSTEM FOR BIOLOGIC MATERIAL SHAPING, PREPARATION, AND INTRAOCULAR STENTING FOR INCREASED AQUEOUS OUTFLOW AND LOWERING OF INTRAOCULAR PRESSUREFebruary 2021November 2024Allow4511NoNo
17177047SYSTEMS, DEVICES, AND METHODS FOR FLUID MONITORINGFebruary 2021January 2022Allow1111NoNo
17175332SHUNTING SYSTEMS WITH ROTATION-BASED FLOW CONTROL ASSEMBLIES, AND ASSOCIATED SYSTEMS AND METHODSFebruary 2021January 2022Allow1110YesNo
17148799PUNCTURE NEEDLE AND METHOD OF USING GUIDE WIREJanuary 2021May 2024Allow4000NoNo
17134733MEDICAL FLUID DELIVERY SYSTEMDecember 2020December 2024Abandon4810NoNo
17254283INDWELLING URINARY CATHETERSDecember 2020December 2024Abandon4801NoNo
17111880DEVICES AND METHODS FOR NEEDLELESS AND NEEDLED EXTRACTION OF CONTENTS FROM VIALSDecember 2020March 2021Allow310NoNo
17101265IMPLANTABLE DIALYSIS DEVICENovember 2020September 2024Allow4611NoNo
17054909Smart Artificial Lung And Perfusion SystemsNovember 2020October 2024Allow4721NoNo
17089176OCULAR IMPLANT DELIVERY SYSTEM AND METHODS THEREOFNovember 2020December 2024Abandon5001NoNo
17088497SYSTEMS AND METHODS FOR IMPLODING LEUKEMIA CELLSNovember 2020November 2024Abandon4810NoNo
17072250Anaerobic Blood Storage ContainersOctober 2020May 2024Allow4310NoNo
17062440Methods of Amelioration of Cerebrospinal Fluid and Devices and Systems ThereforOctober 2020December 2021Allow1421YesNo
17060495DEVICE AND INSTRUMENT FOR TREATMENT OF ELEVATED INTRAOCULAR PRESSUREOctober 2020October 2024Abandon4910NoNo
17041701SYSTEMS AND METHODS FOR OPTIMIZATION OF PLASMA COLLECTION VOLUMESSeptember 2020June 2021Allow820YesNo
17005586DEPLOYING SPLIT-TIP HEMODIALYSIS CATHETER IN A RIGHT ATRIUMAugust 2020July 2024Allow4610NoNo
17004795Anchorless intragastric Device For Treating ObesityAugust 2020September 2024Abandon4901NoNo
16975307CONTROL OR REGULATING DEVICEAugust 2020November 2024Allow5120NoNo
16991435CATHETER, COMPOSITION FOR CATHETER, PRODUCTION METHOD THEREFORAugust 2020September 2024Allow4920NoNo
16988679GALECTIN-3 PLASMAPHERESIS THERAPYAugust 2020June 2024Allow4610NoNo
16944314DEPLOYING SPLIT-TIP HEMODIALYSIS CATHETER IN A RIGHT ATRIUMJuly 2020July 2024Allow4811NoNo
16965408DEVICE FOR THE CONTINUOUS MONITORING OF BLOOD CHARACTERISTIC QUANTITIES IN AN EXTERNAL CARDIOVASCULAR SUPPORTING CIRCUITJuly 2020April 2024Allow4510NoNo
16931333SYSTEM AND METHOD FOR COLLECTING PLASMAJuly 2020February 2021Allow710YesNo
16902545MULTIPART FLUID SYSTEM AND A SYSTEM FOR REGIONAL CITRATE ANTICOAGULATION IN AN EXTRACORPOREAL BLOOD CIRCUITJune 2020August 2024Allow5011NoNo
16891655SELF-SEALING CANNULAJune 2020February 2024Allow4410NoNo
16875053APPLICATOR AND A METHOD FOR THE TRANSPYLORIC PLACEMENT OR REMOVAL OF A TRANSPYLORIC AND/OR A TRANSDUODENAL BYPASS DEVICE IN/FROM THE REGION OF THE PYLORUS OF A PATIENTMay 2020July 2024Allow5001NoNo
16868836Gas Exchange Composite Membranes and Methods of Use ThereofMay 2020November 2023Allow4210NoNo
16866078SYSTEM AND METHOD FOR COLLECTING PLASMAMay 2020February 2021Allow910YesNo
16865837SHIELDING DEVICE USEFUL FOR MANIPULATING A RADIOACTIVE SOLUTIONMay 2020January 2025Abandon5621YesNo
16861854IMPLANTABLE BIOLOGIC STENT AND SYSTEM FOR BIOLOGIC MATERIAL SHAPING, PREPARATION, AND INTRAOCULAR STENTING FOR INCREASED AQUEOUS OUTFLOW AND LOWERING OF INTRAOCULAR PRESSUREApril 2020February 2021Allow1010NoNo
16840108ADJUSTABLE FLOW GLAUCOMA SHUNTS AND METHODS FOR MAKING AND USING SAMEApril 2020July 2021Allow1600NoNo
16840137ADJUSTABLE FLOW GLAUCOMA SHUNTS AND METHODS FOR MAKING AND USING SAMEApril 2020July 2021Allow1600NoNo
16828054METHODS AND DEVICES FOR INCREASING AQUEOUS HUMOR OUTFLOWMarch 2020February 2024Allow4710NoNo
16817107INTEGRATED AUTOTRANSFUSION BOWL AND THE FLUID LINE ORGANIZERMarch 2020October 2023Allow4310NoNo
16805440Flow Regulating Device In The HeartFebruary 2020July 2023Allow4100NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DEAK, LESLIE R.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
10
Examiner Affirmed
7
(70.0%)
Examiner Reversed
3
(30.0%)
Reversal Percentile
46.3%
Lower than average

What This Means

With a 30.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
24
Allowed After Appeal Filing
6
(25.0%)
Not Allowed After Appeal Filing
18
(75.0%)
Filing Benefit Percentile
33.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner DEAK, LESLIE R - Prosecution Strategy Guide

Executive Summary

Examiner DEAK, LESLIE R works in Art Unit 3799 and has examined 322 patent applications in our dataset. With an allowance rate of 86.6%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner DEAK, LESLIE R's allowance rate of 86.6% places them in the 60% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by DEAK, LESLIE R receive 1.68 office actions before reaching final disposition. This places the examiner in the 47% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DEAK, LESLIE R is 39 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +8.2% benefit to allowance rate for applications examined by DEAK, LESLIE R. This interview benefit is in the 40% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 31.7% of applications are subsequently allowed. This success rate is in the 58% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 38.9% of cases where such amendments are filed. This entry rate is in the 52% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 20.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 25% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 60.0% of appeals filed. This is in the 32% percentile among all examiners. Of these withdrawals, 33.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 34.8% are granted (fully or in part). This grant rate is in the 30% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.7% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 44% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.